Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo
 

Histórico de pesquisa  ()

Sua seleção  ()

 0 documento(s) selecionado(s).

Refine sua pesquisa

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (1092)
Idioma
Ano de publicação

Enviar por email

Você tem 0 documento(s) selecionado(s).

Nenhum documento selecionado

 
Resultados  1-12 de 1.383
1.

Informe diário de evidências COVID-19: busca realizada em 19 de junho de 2020/ COVID-19 daily evidence report: search conducted on June 19, 2020

Autor(es): Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde
Fonte: Brasília; s.n; 19 jun. 2020.
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 1100432
Resumo: O Informe Diário de Evidências é uma produção do Ministério da Saúde que tem como objetivo acompanhar diariamente as publicações científicas sobre tratamento farmacológico e vacinas para a COVID-19. Dessa forma, são realizadas buscas estruturadas em bases de dados biomédicas, referente ao dia anterior desse informe. Não são incluídos estudos pré-clínicos (in vitro, in vivo, in silico). A frequência dos estudos é demonstrada de acordo com a sua classificação metodológi (mais)
2.

Uso do Oseltamivir em Síndromes Respiratórias: revisão sistemática rápida/ Use of Oseltamivir in Respiratory Syndromes: a quick systematic review

Autor(es): Goiás (Estado). Secretaria da Saúde
Fonte: s.l; s.n; 11 abr. 2020.
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 1116265
Resumo: Contexto: Os vírus da gripe são importantes patógenos globais, cujas taxas de incidência resultam em substancial incidência de doenças, hospitalização e mortalidade. O oseltamivir é um medicamento comumente usado e armazenado contra pandemias passadas e futuras com base em normas internacionais e recomendações nacionais. O tratamento preconizado pela OrganizaÇão Mundial de Saúde (OMS), para casos graves de influenza, é o oseltamivir. A infecção pelo novo coronavírus (COVID (mais)
3.

Uso de oseltamivir para el tratamiento de pacientes con COVID-19/ Use of oseltamivir for the treatment of patients with COVID-19

Autor(es): Peru. EsSalud. Instituto de Evaluación de Tecnologías en Salud e Investigación
Fonte: s.l; IETSI; 14 mar. 2020.
LILACS - Literatura Latino-Americana e do Caribe em Ciências da Saúde ID: 1096058
Resumo: INTRODUCCIÓN: Oseltamivir (Tamiflu ®) es un producto farmacéutico con indicación para el tratamiento y prevención de la gripe por influenza en adultos y en niños1 . A la fecha, ninguna organización internacional, incluyendo la CDC de EEUU2 o la OMS3 ha establecido recomendaciones específicas para el manejo clínico de pacientes con COVID-19 con antivirales o terapias inmunomoduladoras. Esto es, no se dispone de recomendaciones para el uso de Oseltamivir u otro antirretroviral en pac (mais)
4.

Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies.

Autor(es): Ilyushina, Natalia A; Komatsu, Takashi E; Ince, William L; Donaldson, Eric F; Lee, Nicolette; O'Rear, Julian J; Donnelly, Raymond P
Fonte: Virol J;16(1): 149, 2019 11 29.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31783761
Resumo: BACKGROUND: Vaccination and the use of neuraminidase inhibitors (NAIs) are currently the front lines of defense against seasonal influenza. The activity of influenza vaccines and antivirals drugs such as the NAIs can be affected by mutations in the influenza hemagglutinin (HA) protein. Numerous HA substitutions have been identified in nonclinical NAI resistance-selection experiments as well as in clinical specimens from NAI treatment or surveillance studies. These mutations are listed in th (mais)
5.

Perfil clínico-epidemiológico de las defunciones por influenza con antecedente de vacunación oportuna, México 2010-2018.

Autor(es): Kuri-Morales, Pablo Antonio; Castillo-Flores, Guadalupe Díaz Del; Castañeda-Prado, Andrés; Pacheco-Montes, Salma Rosario
Fonte: Gac Med Mex;155(5): 457-463, 2019.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31695227
Resumo: Introduction: Influenza epidemics are of higher risk at the extremes of life and in people with comorbidities. Effective -vaccination prevents the occurrence of serious cases and decreases mortality. Objective: To describe deaths from influenza with a history of timely vaccination, from the 2010 to the 2018 season in Mexico. Method: Cross-sectional, descriptive study where the Influenza Epidemiological Surveillance System database was used. Results: From 2010 to 2018, 65 vaccinated individu (mais)
6.

Effectiveness of four types of neuraminidase inhibitors approved in Japan for the treatment of influenza.

Autor(es): Mawatari, Momoko; Saito, Reiko; Hibino, Akinobu; Kondo, Hiroki; Yagami, Ren; Odagiri, Takashi; Tanabe, Ikumi; Shobugawa, Yugo
Fonte: PLoS One;14(11): e0224683, 2019.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31697721
Resumo: BACKGROUND: Neuraminidase inhibitors (NAIs) effectively treat influenza. The clinical effectiveness of four NAIs (oseltamivir, zanamivir, laninamivir, and peramivir) was evaluated against influenza A/H1N1pdm09, A/H3N2, and B viruses. Additionally, fever duration in patients infected with oseltamivir-resistant influenza A/H1N1pdm09 with the H275Y mutation was evaluated. METHODS: Patients aged <20 years who visited outpatient clinics in Japan with influenza-like illnesses were enrolled during (mais)
7.

Oseltamivir Is Effective against 1918 Influenza Virus Infection of Macaques but Vulnerable to Escape.

Autor(es): Feldmann, Friederike; Kobasa, Darwyn; Embury-Hyatt, Carissa; Grolla, Allen; Taylor, Tracy; Kiso, Maki; Kakugawa, Satoshi; Gren, Jason; Jones, Steven M; Kawaoka, Yoshihiro; Feldmann, Heinz
Fonte: mBio;10(5)2019 10 22.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31641086
Resumo: The 1918 influenza virus, subtype H1N1, was the causative agent of the most devastating pandemic in the history of infectious diseases. In vitro studies have confirmed that extreme virulence is an inherent property of this virus. Here, we utilized the macaque model for evaluating the efficacy of oseltamivir phosphate against the fully reconstructed 1918 influenza virus in a highly susceptible and relevant disease model. Our findings demonstrate that oseltamivir phosphate is effective in pre (mais)
8.

Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice.

Autor(es): Takahashi, E; Sawabuchi, T; Kimoto, T; Sakai, S; Kido, H
Fonte: J Dairy Sci;102(11): 9559-9569, 2019 Nov.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31495632
Resumo: Antiviral neuraminidase inhibitors, such as oseltamivir, zanamivir, and peramivir, are widely used for treatment of influenza virus infection. We reported previously that oseltamivir inhibits the viral growth cycle, ameliorates symptoms, and reduces viral antigen quantities. Suppressed viral antigen production, however, induces a reduction of acquired antiviral humoral immunity, and increases the incidence of re-infection rate in the following year. To achieve effective treatment of influen (mais)
9.

Molecular characterization of influenza A(H1N1)pdm09 viruses circulating at various geographical locations in India, 2017.

Autor(es): Potdar, Varsha; Vijay, Neetu; Gupta, Nivedita; Arunkumar, G; Borkakoty, Bishwajyoti; Malhotra, Bharti; Rabha, Debajit; Hinge, Dilip; Kaur, Harmanmeet; Chadha, Mandeep
Fonte: Indian J Med Res;149(6): 783-789, 2019 06.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31496532
Resumo: Background & objectives: Influenza virological surveillance is an essential tool for the early detection of novel genetic variants of epidemiologic and clinical significance. This study was aimed to genetically characterize A(H1N1)pdm09 virus circulating in 2017 and to compare it with the global data. Methods: The regional/State Viral Research and Diagnostic Laboratories (VRDLs) provided influenza diagnosis for referred clinical samples and shared influenza A(H1N1)pdm09 positives with the I (mais)
10.

Growth activation of influenza virus by trypsin and effect of T-705 (favipiravir) on trypsin-optimized growth condition.

Autor(es): Daikoku, T; Okuda, T; Kawai, M; Morita, N; Tanaka, T; Takemoto, M; Fukuda, Y; Takahashi, K; Nomura, N; Shiraki, K
Fonte: Acta Virol;63(3): 309-315, 2019.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31507197
Resumo: Influenza virus is activated by proteolytic cleavage of hemagglutinin by trypsin. After determining the optimal trypsin concentration, intracellular and extracellular influenza A/PR/8/34 (H1N1) and A/Victoria/361/2011 (H3N2) virus productions were compared in cultures treated with T-705 (favipiravir) and GS 4071 (an active form of oseltamivir). Although both drugs efficiently inhibited extracellular viral RNA release in a dose-dependent manner, T-705 inhibited it to the level of the inoculu (mais)
11.

Exploration of the mechanisms of Ge Gen Decoction against influenza A virus infection.

Autor(es): Geng, Zi-Kai; Li, Ya-Qun; Cui, Qing-Hua; DU, Rui-Kun; Tian, Jing-Zhen
Fonte: Chin J Nat Med;17(9): 650-662, 2019 Sep.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31526500
Resumo: Ge Gen Decoction (GGD), a Traditional Chinese Medicine prescription, is mainly used to treat infectious respiratory diseases and can relieve the symptoms of influenza A virus (IAV) infection. However, the underlying mechanism of GGD against IAV infection remains unclear. In this study, we found that GGD had moderate anti-IAV activity in vitro. GGD was more effective when given before the viral infection and targeted the viral attachment and replication stages rather than the internalization (mais)
12.

MDCK-B4GalNT2 cells disclose a α2,3-sialic acid requirement for the 2009 pandemic H1N1 A/California/04/2009 and NA aid entry of A/WSN/33.

Autor(es): Wong, Ho Him; Fung, Kevin; Nicholls, John M
Fonte: Emerg Microbes Infect;8(1): 1428-1437, 2019.
MEDLINE - Literatura Internacional em Ciências da Saúde PMID: 31560252
Resumo: Switching of receptor binding preference has been widely considered as one of the necessary mutations for avian influenza viruses, enabling efficient transmissions between human hosts. By stably overexpressing B4GalNT2 gene in MDCK cells, surface α2,3-siallylactose receptors were modified without affecting α2,6-receptor expression. The cell line MDCK-B4GalNT2 was used as a tool to screen for α2,3-receptor requirements in a panel of influenza viruses with previously characteri (mais)
Resultados  1-12 de 1.383